Literature DB >> 11279632

Effects of HIV infection on age and cause of death for persons with hemophilia A in the United States.

T L Chorba1, R C Holman, M J Clarke, B L Evatt.   

Abstract

Because of changes in factor replacement therapy and in treatment of human immunodeficiency virus (HIV) infection, we examined death record data for persons with hemophilia A in the United States to evaluate effects of HIV infection on age and causes of death. Multiple cause-of-death data from 1968 through 1998 were examined to assess death rates for persons with hemophilia A. ICD-9 coded causes of death from 1979 through 1998 were examined to assess long-term trends. From 1979 through 1998, 4,781 deaths among persons with hemophilia A were reported, of which 2,254 (47%) had HIV-related disease listed as a cause of death. In the late 1980s, mortality among persons with hemophilia A increased markedly, and the age-adjusted death rate peaked at 1.5 per 1,000,000 population in 1992. Median age at death decreased from 55 years in 1979-1982 to 40.5 years in 1987-1990, and increased to 46 years in 1995-1998. In the period 1995-1998, the median age of hemophilia A decedents with HIV-related disease was 33 years, compared to 72 years for those without HIV-related disease; the most frequently listed causes of death for those without HIV-related disease were hemorrhagic and circulatory phenomena; the most frequently listed for those with HIV-related disease were diseases of liver and the respiratory system. From 1995 to 1998, hemophilia A-associated deaths decreased by 41%, with a 78% decrease among those who had HIV-related disease. Although HIV infection has adversely effected mortality for persons with hemophilia A, the marked recent decrease in the death rate among persons with hemophilia A appears to reflect advances in care for those with HIV-related disease and is consistent with a decline in HIV mortality observed in the general population.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11279632     DOI: 10.1002/ajh.1050

Source DB:  PubMed          Journal:  Am J Hematol        ISSN: 0361-8609            Impact factor:   10.047


  17 in total

1.  Pathogen safety of long-term treatments for bleeding disorders: still relevant to current practice.

Authors:  Giovanni Di Minno; Mariana Canaro; James W Ironside; David Navarro; Carlo Federico Perno; Andreas Tiede; Lutz Gürtler
Journal:  Haematologica       Date:  2013-10       Impact factor: 9.941

2.  Knowledge, attitudes, and behaviors of youths in the US hemophilia population: results of a national survey.

Authors:  Ann-Marie Nazzaro; Sally Owens; W Keith Hoots; Kelly L Larson
Journal:  Am J Public Health       Date:  2006-07-27       Impact factor: 9.308

3.  Gene therapy for hemophilia: the clot thickens.

Authors:  Katherine A High
Journal:  Hum Gene Ther       Date:  2014-11       Impact factor: 5.695

4.  A case-control study reveals immunoregulatory gene haplotypes that influence inhibitor risk in severe haemophilia A.

Authors:  J N Lozier; P S Rosenberg; J J Goedert; I Menashe
Journal:  Haemophilia       Date:  2011-03-01       Impact factor: 4.287

5.  DeepDeath: Learning to predict the underlying cause of death with Big Data.

Authors:  Hamid Reza Hassanzadeh; May D Wang
Journal:  Conf Proc IEEE Eng Med Biol Soc       Date:  2017-07

6.  Potency and mass of factor VIII in FVIII products.

Authors:  S Butenas; B Parhami-Seren; M T Gissel; E D Gomperts; D N Fass; K G Mann
Journal:  Haemophilia       Date:  2008-08-06       Impact factor: 4.287

7.  Inhibitors and mortality in persons with nonsevere hemophilia A in the United States.

Authors:  Ming Y Lim; Dunlei Cheng; Michael Recht; Christine L Kempton; Nigel S Key
Journal:  Blood Adv       Date:  2020-10-13

8.  Prevalence and risk factors for hypertension in hemophilia.

Authors:  Annette von Drygalski; Nicholas A Kolaitis; Ricki Bettencourt; Jaclyn Bergstrom; R Kruse-Jarres; Doris V Quon; Christina Wassel; Ming C Li; Jill Waalen; Darlene J Elias; Laurent O Mosnier; Matthew Allison
Journal:  Hypertension       Date:  2013-04-29       Impact factor: 10.190

9.  Causes of death and mortality trends related to hemophilia in Brazil, 1999 to 2016.

Authors:  Augusto Hasiak Santo
Journal:  Hematol Transfus Cell Ther       Date:  2020-06-04

10.  Antihemophilic factor (recombinant) plasma/albumin-free method for the management and prevention of bleeding episodes in patients with hemophilia A.

Authors:  Steven Pipe
Journal:  Biologics       Date:  2009-07-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.